1. Scrip
  2. >>New Products

Amylyx Will Submit ALS Drug For Approval In The Coming Months

Continues ‘As Fast As Possible’ Approach With AMX0035

 
• By Mandy Jackson

After discussions with the US FDA, the company determined it can file AMX0035 based on Phase II/III results and interim Phase III data. Amylyx is sticking with its go-it-alone strategy for global commercialization.

Physiotherapist assisting a patient with Amyotrophic Lateral Sclerosis
AMX0035 slowed disease progression in CENTAUR as assessed by an ALS functional rating scale • Source: Alamy

Amylyx Pharmaceuticals, Inc. said on 15 September that it will submit a new drug application (NDA) to the US Food and Drug Administration “in the coming months” seeking approval for AMX0035 to treat amyotrophic lateral sclerosis (ALS), well before completion of its soon-to-be-initiated Phase III clinical trial. The FDA filing plan is a shift from just two months ago when the Cambridge, MA-based private company, which intends to commercialize its drug globally on its own, raised $135m to fund the Phase III study and file AMX0035 with Canadian and EU regulators.

Exactly when Amylyx could file in the US was unclear as recently as July, when the company announced its new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

J&J Delivers In Q2 Despite Stelara Drop, Raising Guidance

 
• By Jessica Merrill

Stelara revenues declined 42.7% in the quarter due to biosimilars, but innovative medicines grew 4.9%, surpassing $15bn for the quarter. Although pharma tariffs could be coming, the firm said the impact continues to be hard to predict.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

In Brief: Nanoscope Ploughs Forward With FDA Application For Retinitis Pigmentosa Gene Therapy

 
• By Manas Mishra

Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?